Top Stock Picks of 2026: Bristol-Myers Squibb

For the final few weeks of the first quarter we're going to highlight one of Schaeffer's top 15 picks for 2026. Today, we have drugmaker Bristol-Myers Squibb Co (NYSE:BMY). To access the entirety of the 2026 report, click here.

The following is our analysis from Dec. 23 for the upcoming year.

If interest rates are lower or stable in 2026, capital reallocates from high-multiple growth names to long-duration, cash generative equities. Pharma stock Bristol-Myers Squibb (BMY) could stand to benefit from this rotation, screening extremely well on free cashflow yield and dividend sustainability.

Thanks to this rotation starting at the end of 2025, BMY has reclaimed its 200-month moving average, as well as a long-term trendline connecting higher highs from 2004-2012.

The shares could test their March 2025 highs of $63, nearly 18% upside from this report. If that peak doesn't cap sustained moves higher, there is as much as a 40% upside towards its former long-term high at $75, which could be attained in the next 12 months.